EVIDENCE BASED FORMULARY DECISION SUPPORT

According to a recent survey, 75% of hospitals utilize their internal pharmacy staff to prepare and create drug reviews for P&T. Gathering the supporting data about these drugs requires searching multiple sources: clinical journals, FDA announcements, medical conference summaries, presentations, industry newsletters, and pharmaceutical company announcements. This process takes clinical pharmacists away from participating at the point of care, between 10 and 20 hours per month! 
 
Yet, survey respondents either wait until after a drug received FDA approval to begin evaluating the drugs' appropriateness for their formulary; only review high cost drugs prior to FDA approval; or sometimes review a practice-changing drug prior to approval. 
 
One could postulate that this practice of post FDA approval review aligns with point-of-care availability of newly approved drug information in knowledgebases feeding point-of-care patient record software. 
 
However, pre-FDA efficient drug approval review is possible by re-purposing staff time toward analysis rather than data-gathering. The following benefits accrue:

1. patient populations that benefit from breakthrough technologies receive new treatments sooner.
2. more time to plan for efficient and economical adoption of practice changing treatments.
3. earlier prescriber education materials.
4. more time to determine how to mitigate the impact of extremely expensive therapies. ​

A single source of critical, unbiased, comprehensive information about the pharmaceutical pipeline is available to prospectively prepare the P&T evaluation of new drugs. The Pharmaceutical Pipeline Tracker was created to fulfill the need. The web-delivered easily searchable knowledgebase includes information to create P&T drug reviews: generic names, brand names (if known), indication, therapeutic area, mechanism of action, route, PDUFA Date (if established), FDA status (Phase I, II, III, or approved) efficacy and safety. 
 
Evidence based decision support within the Pharmaceutical Pipeline Tracker includes a summary of efficacy and safety along with the latest news and analysis from clinical journals, FDA announcements, medical conference summaries, presentations, industry newsletters, and pharmaceutical company announcements. As a bonus, there is additional evidence via links to published studies via PubMed. 
 
It’s time to re-think how you prepare for P&T new drug reviews.
Click here for access to The Pharmaceutical Pipeline Tracker for only $339! Utilize all of the functions and access all of the evidence based intelligence about 888 investigational drugs in the pipelines of over 400 pharmaceutical companies. Access includes links to 1546 late stage clinical trial results. Limited time offer. No automatic renewal.